0001104659-22-005599.txt : 20220119
0001104659-22-005599.hdr.sgml : 20220119
20220119203224
ACCESSION NUMBER: 0001104659-22-005599
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220114
FILED AS OF DATE: 20220119
DATE AS OF CHANGE: 20220119
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vogt Frederick G
CENTRAL INDEX KEY: 0001719678
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36860
FILM NUMBER: 22540354
MAIL ADDRESS:
STREET 1: 2120 HEMLOCK RD.
CITY: WEST NORRITON
STATE: PA
ZIP: 19403
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IOVANCE BIOTHERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001425205
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 753254381
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 999 SKYWAY ROAD
STREET 2: SUITE 150
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
BUSINESS PHONE: 6502607120
MAIL ADDRESS:
STREET 1: 999 SKYWAY ROAD
STREET 2: SUITE 150
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
FORMER COMPANY:
FORMER CONFORMED NAME: Lion Biotechnologies, Inc.
DATE OF NAME CHANGE: 20131015
FORMER COMPANY:
FORMER CONFORMED NAME: Genesis Biopharma, Inc
DATE OF NAME CHANGE: 20100319
FORMER COMPANY:
FORMER CONFORMED NAME: FREIGHT MANAGEMENT CORP
DATE OF NAME CHANGE: 20080128
4
1
tm223806-4_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-01-14
0
0001425205
IOVANCE BIOTHERAPEUTICS, INC.
IOVA
0001719678
Vogt Frederick G
C/O IOVANCE BIOTHERAPEUTICS, INC.
825 INDUSTRIAL ROAD, 4TH FLOOR
SAN CARLOS
CA
94070
0
1
0
0
Interim CEO & General Counsel
Restricted Stock Units
2022-01-14
4
A
0
250000
0
A
Common Stock
250000
250000
D
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.
/s/ Frederick G. Vogt
2022-01-19